文献速递骨质疏松与代谢性骨病

CYP1A1基因在长期糖皮质激素相关不良反应中的作用

The role of the CYP1A1 gene in long-term glucocorticoid-related adverse effects.
PubMed 文献 · Osteoporos Int · 2026-10-27

UNLABELLED: CYP1A1 gene variants may influence the development of AE of chronic GC treatment. The rs1799814 polymorphism was associated with increased BMI and lower levels of bone turnover markers, independent of GC dose, suggesting reduced GC metabolism.…

要点

  • CYP1A1 rs1799814多态性与长期糖皮质激素治疗者更高的BMI及5年间BMI增加相关。
  • rs1799814多态性者骨转换标志物NTx更低,提示糖皮质激素代谢减慢。
  • 未发现CYP1A1多态性与骨质疏松、骨折、骨密度或TBS相关。

核心结论

  • CYP1A1 rs1799814多态性与更严重的糖皮质激素相关不良反应相关,提示糖皮质激素代谢减慢。

主要发现

  • 检出4种CYP1A1多态性:rs41279188、rs1048943、rs1799814和rs4646422,分别有1、9、9和1例患者携带。
  • rs1799814多态性患者(13%)BMI更高(29.3 vs. 25.5;p=0.019),5年间BMI变化更大(ΔBMI:1.7 vs. -0.32;p=0.02;校正累积GC剂量)。
  • rs1799814多态性患者骨转换标志物更低:NTx 21 vs. 40 nMol/mMol(p=0.003),CTx 0.16 vs. 0.29 ng/mL(p=0.068),OC 16.6 vs. 19.3 ng/mL(p=0.059)。
  • 未发现CYP1A1多态性与骨质疏松和/或骨折、骨密度或TBS值之间的关联。

临床怎么用

  • 对于长期糖皮质激素治疗患者,CYP1A1 rs1799814多态性可能提示更高的BMI增加风险及骨转换抑制,但尚不能用于预测骨质疏松或骨折风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: CYP1A1 gene variants may influence the development of AE of chronic GC treatment. The rs1799814 polymorphism was associated with increased BMI and lower levels of bone turnover markers, independent of GC dose, suggesting reduced GC metabolism. No association was found with OP and/or Fx, BMD or TBS values. INTRODUCTION: Long-term glucocorticoid (GC) use can produce adverse effects (AE) including obesity, diabetes, osteoporosis and fractures. The variability in AE severity suggests a genetic influence. CYP1A1, a cytochrome P450 family enzyme involved in GC metabolism, may play a role. This study aimed to genotype CYP1A1 variants in patients on chronic GC treatment and analyse their relationship with long-term AE. METHODS: Seventy patients (56 ± 16.6 years; 71.4% female; 47.1% postmenopausal) receiving chronic GC treatment ( ≥5 mg/ day for >3 months) were included. Clinical data were collected at baseline and at 5 years of follow-up, including OP risk factors, previous and incidental fractures, GC dose and duration, disease activity, anthropometric data, bone metabolism parameters, bone mineral density (BMD) and trabecular bone score (TBS) (by DXA), and vertebral fractures (X-ray). CYP1A1 gene sequencing was performed by NGS using Amplicon Deep Sequencing on an Ion Torrent platform. RESULTS: Four CYP1A1 polymorphisms were identified: rs41279188, rs1048943, rs1799814 and rs4646422. Nine patients had rs1048943, nine rs1799814, one rs4646422 and one rs41279188 polymorphisms, respectively. Patients with the rs1799814 polymorphism (13%) had higher BMI (29.3 vs. 25.5; p = 0.019) and greater BMI change over 5 years (ΔBMI: 1.7 vs. -0.32; p = 0.02; adjusted for cumulative GC dose). Additionally, they presented lower bone turnover markers (NTx: 21 vs. 40 nMol/mMol, p = 0.003, CTx: 0.16 vs. 0.29 ng/mL, p = 0.068, OC: 16.6 vs. 19.3 ng/mL, p = 0.059). No associations were found between CYP1A1 polymorphisms and the presence of osteoporosis and/or fractures, BMD or TBS values. CONCLUSION: The CYP1A1 rs1799814 polymorphism is associated with more severe GC-related AE, suggesting reduced GC metabolism.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Florez H, Gonzalez E, Cajiao K, et al. The role of the CYP1A1 gene in long-term glucocorticoid-related adverse effects. Osteoporos Int. 2026. PMID: 42944907. doi:10.1007/s00198-026-08253-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。